DDInter1123 DDInter1600
Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. Mannitol may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a renal function diagnostic aid. On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for this indication under the name BRONCHITOL® by Chies
Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III. Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment.
Mannitol {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Rabeprazole
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Riociguat
Mannitol {u} (Compound) causes {v} (Side Effect) Nervousness
Nervousness {u} (Side Effect) is caused by {v} (Compound) Dipyridamole
Dipyridamole {u} may lead to a major life threatening interaction when taken with {v} Riociguat
Mannitol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Riociguat
Mannitol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dipyridamole
Dipyridamole {u} may lead to a major life threatening interaction when taken with {v} Riociguat
Mannitol (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Mannitol (Compound) causes Nervousness (Side Effect) and Nervousness (Side Effect) is caused by Dipyridamole (Compound) and Dipyridamole may lead to a major life threatening interaction when taken with Riociguat
Mannitol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ivacaftor (Compound) and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Mannitol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dipyridamole (Compound) and Dipyridamole may lead to a major life threatening interaction when taken with Riociguat